Round 2 U2D2 Proposals have been funded!

The UICentre and the UI Cancer are continuing their collaboration to provide seed grants ($25K each) for promising new cancer therapeutic approaches. Today we announce our second round of awards, which are directed to prostate cancer:

Development of IGF1R inhibitors with reduced INSR-cross reactivity to target SOX2-positive prostate cancer
Team: Donald Vander Griend (PI), Associate Professor, Pathology; Malaika Argade (Co-I), Research Scientist, UICentre.
Focus: optimize IGF1R inhibitors to resensitize prostate cancer cells to anti-androgen therapy

Allosteric binders of BiP for Prostate Cancer
Team: Jeremy Johnson (PI), Professor, Pharmacy Practice.
Focus: identify allosteric inhibitors of a chaperone protein of the androgen receptor. Such compounds could form the basis of a new therapy for prostate cancer.